Evidence map›Paper›PMID 32337371›Full record

ReviewNPJ digital medicine2020

Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs).

Jennifer C Goldsack, Andrea Coravos, Jessie P Bakker, Brinnae Bent, Ariel V Dowling, Cheryl Fitzer-Attas, Alan Godfrey, Job G Godino, Ninad Gujar, Elena Izmailova and 6 more

Abstract readReview
In one paragraph

Review in NPJ digital medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 329 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
329citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

329 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. A patient first perspective of sleep disturbance across therapeutic areas: a systematic literature review of qualitative studies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

269 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jennifer C GoldsackDigital Medicine Society (DiMe), Boston, MA USA.
Andrea CoravosDigital Medicine Society (DiMe), Boston, MA USA.ORCID 0000-0001-5379-3540
Jessie P BakkerDigital Medicine Society (DiMe), Boston, MA USA.
Brinnae Bent5Biomedical Engineering Department, Duke University, Durham, NC USA.
Ariel V DowlingTakeda Pharmaceuticals, Cambridge, MA USA.ORCID 0000-0002-7889-4978
Cheryl Fitzer-AttasClinMed LLC, Dayton, NJ USA.
Alan Godfrey8Computer and Information Sciences Department, Northumbria University, Newcastle-upon-Tyne, UK.ORCID 0000-0003-4049-9291
Job G Godino9Center for Wireless and Population Health Systems, University of California, San Diego, CA USA.
Ninad GujarSamsung Neurologica, Danvers, MA USA.ORCID 0000-0001-7901-308X
Elena IzmailovaDigital Medicine Society (DiMe), Boston, MA USA.
Christine MantaDigital Medicine Society (DiMe), Boston, MA USA.
Barry PetersonIndependent Consultant, Charlotte, NC USA.
Benjamin VandendriesscheByteflies, Antwerp, Belgium.ORCID 0000-0003-0672-0327
William A Wood16Department of Medicine, University of North Carolina at Chapel Hill; Lineberger Comprehensive Cancer Center, Chapel Hill, NC USA.
Ke Will Wang5Biomedical Engineering Department, Duke University, Durham, NC USA.
Jessilyn Dunn5Biomedical Engineering Department, Duke University, Durham, NC USA.ORCID 0000-0002-3241-8183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital medicine is an interdisciplinary field, drawing together stakeholders with expertize in engineering, manufacturing, clinical science, data science, biostatistics, regulatory science, ethics, patient advocacy, and healthcare policy, to name a few. Although this diversity is undoubtedly valuable, it can lead to confusion regarding terminology and best practices. There are many instances, as we detail in this paper, where a single term is used by different groups to mean different things, as well as cases where multiple terms are used to describe essentially the same concept. Our intent is to clarify core terminology and best practices for the evaluation of Biometric Monitoring Technologies (BioMeTs), without unnecessarily introducing new terms. We focus on the evaluation of BioMeTs as fit-for-purpose for use in clinical trials. However, our intent is for this framework to be instructional to all users of digital measurement tools, regardless of setting or intended use. We propose and describe a three-component framework intended to provide a foundational evaluation framework for BioMeTs. This framework includes (1) verification, (2) analytical validation, and (3) clinical validation. We aim for this common vocabulary to enable more effective communication and collaboration, generate a common and meaningful evidence base for BioMeTs, and improve the accessibility of the digital medicine field.

Indexed as

Research dataScientific community

Identifiers

PMID32337371
PMCPMC7156507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.